Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics

Journal of Child and Adolescent Psychopharmacology

Volumn 23, Issue 10, 2013, Pages 665-675

  Stentebjerg Olesen, Marie ^a   Jeppesen, Pia ^a   Pagsberg, Anne K ^a   Fink Jensen, Anders ^b,c   Kapoor, Sandeep ^d   Chekuri, Raja ^d   Carbon, Maren ^d   Al Jadiri, Aseel ^d   Kishimoto, Taishiro ^d,e,f   Kane, John M ^d,e,f,g   Correll, Christoph U ^d,e,f,g  

^a Mental Health Centre for Child and Adolescent Psychiatry   (Denmark)

^b University Mental Health Centre   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d ZUCKER HILLSIDE HOSPITAL   (United States)

^e DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^f FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADOLESCENT; ADULT; AKATHISIA; ARTICLE; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRESCHOOL CHILD; SCHIZOPHRENIA; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; CHILD; FEMALE; HUMANS; LOGISTIC MODELS; MALE; PREDICTIVE VALUE OF TESTS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84890663120     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2013.0007     Document Type: Article

References (44)

1. Agid O, Kapur S, Arenovich T, Zipursky RB: Delayed-onset hypothesis of antipsychotic action: A hypothesis tested and rejected. Arch Gen Psychiatry 60:1228-1235, 2003.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
3. Amminger GP, Henry LP, Harrigan SM, Harris MG, Alvarez-Jimenez M, Herrman H, Jackson HJ, McGorry PD: Outcome in early-onset schizophrenia revisited: Findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study. Schizophr Res 131:112-119, 2011.
4. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR: Remission in schizophrenia: Proposed criteria and crationale for consensus. Am J Psychiatry 162:441-449, 2005.
5. Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A: Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull 34:1163-1171, 2008a.
6. Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J Clin Psychiatry 69:1580-1588, 2008b.
7. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676, 1989.
8. Berk M, Ng F, Dodd S, Callaly T, Campbell S, Bernardo M, Trauer T: The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use. J Eval Clin Pract 14:979-983, 2008.
9. Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woerner M, Kane JM, Alvir J, Lieberman JA: Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in nevermedicated schizophrenic patients. Am J Psychiatry 152:1724-1729, 1995.
10. Correll CU, Cañas F, Larmo I, Levy P, Montes JM, Fagiolini A, Papageorgiou G, Rossi A, Sturlason R, Zink M: Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups. Eur Psychiatry 26:3-16, 2011a.
11. Correll CU, Kishimoto T, Nielsen J, Kane JM: Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther 33:B16-39, 2011b.
12. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM: Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 59:441-448, 2003.
13. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765-1773, 2009.
14. Correll CU, Zhao Q, Carson WH, Marcus R, McQuade R, Forbes A, Mankoski R: Validity of early antipsychotic response to aripiprazole in adolescents with schizophrenia and its predictive value for clinical outcomes. J Am Acad Child Adolesc Psychiatry 52:689-698, 2013.
15. Derks EM, Fleischhacker WW, Boter H, Peuskens J, Kahn RS: Antipsychotic drug treatment in first-episode psychosis. Should patients be switched to a different antipsychotic drug after 2, 4 or 6 weeks of nonresponse? J Clin Psychopharmacol 30:176-180, 2010.
16. Emsley R, Rabinowitz J, Medori R: Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry 163:743-745, 2006.
17. Gallego JA, Robinson DG, Sevy SM, Napolitano B, McCormack J, Lesser ML, Kane JM: Time to treatment response in first-episode schizophrenia: Should acute treatment trials last several months? J Clin Psychiatry 72:1691-1696, 2011.
18. Guy W: Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, revised, Rockville, MD: National Institute of Mental Health; 1976.
19. Hatta K, Otachi T, Sudo Y, Hayakawa T, Ashizawa Y, Takebayashi H, Hayashi N, Hamakawa H, Ito S, Nakase R, Usui C, Nakamura H, Hirata T, Sawa Y: Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. Schizophr Bull 128:127-135, 2011.
20. Hollingshead AB: A four-factor index of social status. Unpublished working paper, Department of Sociology, Yale University, New Haven, CT, 1975.
21. Kane JM, Leucht S, Carpenter D, Docherty JP, Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders: The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: Methods, commentary, and summary. J Clin Psychiatry 64:5-19, 2003.
22. Kane JM, Correll CU: Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 71:1115-1124, 2010.
23. Kapur S, Arenovich T, Agid I, Zipursky R, Lindborg S, Jones B: Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry 162:939-946, 2005.
24. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276, 1987.
25. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Wlaker S, Sniadecki JL, Kane J: Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 102:230-240, 2008.
26. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM: Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 35:581-590, 2010.
27. Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen A, Weiden P: Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 29:309-314, 1993.
28. Lambert M, Naber D, Eich FX, Schacht M, Linden M, Schimmelmann BG: Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatr Scand115:106-13, 2007.
29. Lambert M, Schimmelmann BG, Naber D, Eich FX, Schulz H, Huber CG, Karow A: Early-and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry 42:277-283, 2009.
30. Leucht S, Busch R, Hamann J, Kissling W, Kane JM: Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 57:1543-1549, 2005.
31. Leucht S, Busch R, Kissling W, Kane J: Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry 68:352-360, 2007.
32. Leucht S, Engel RR: The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. Neuropsychopharmacology 31:406-412, 2006.
33. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR: Linking the PANSS, BPRS, and CGI: Clinical implications. Neuropsychopharmacology 31:2318-2325, 2006.
34. Leucht S, Shamsi SA, Busch R, Kissling W, Kane JM: Predicting antipsychotic drug response-replication and extension to six weeks in an international olanzapine study. Schizophr Res 101:312-319, 2008.
35. Levine SZ, Rabinowitz J, Case M, Ascher-Svanum H: Treatment response trajectories and their antecedents in recent-onset psychosis: A 2-year prospective study. J Clin Psychopharmacol 30:446-449, 2010.
36. Liu-Seifert H, Adams DH, Kinon BJ: Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 23:3-21, 2005.
37. Overall JE: The Brief Psychiatric Rating Scale. Psychological Measurements in Psychopharmacology. Mod Probl Pharmacopsychiatry 7:67-78, 1974.
38. Schennach-Wolff R, Seemuller FH, Mayr A, Maier W, Klingberg S, Heuser I, Klosterkötter J, Gastpar M, Häfner H, Sauer H, Schneider F, Gaebel W, Jäger M, Mö ller HJ, Riedel M: An early improvement threshold to predict response and remission in first-episode schizophrenia. Br J Psychiatry 196:460-466, 2010.
39. Schimmelmann BG, Conus P, Cotton S, McGorry PD, Lambert M: Pre-treatment, baseline, and outcome differences between earlyonset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients. Schizophr Res 95:1-8, 2007.
40. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S: A childrens global assessment scale (CGAS). Arch Gen Psychiatry 40:1228-1231, 1983.
41. Sheehan DV. The Anxiety Disease. New York: Scribner; 1983.
42. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11-19, 1970.
43. Stauffer VL, Case M, Kinon BJ, Conley R, Ascher-Svanum H, Kollack-Walker S, Kane J, McEvoy J, Lieberman J: Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res 187:42-48, 2011.
44. Wilbur R, Kulik FA, Kulik AV: Noradrenergic effects in tardive dyskinesia, akathisia and pseudoparkinsonism via the limbic system and basal ganglia. Prog Neuropsychopharmacol Biol Psychiatr 12:849-864, 1988.